First Allied Advisory Services Inc. Decreases Position in Valeant Pharmaceuticals International, Inc. (VRX)

First Allied Advisory Services Inc. trimmed its holdings in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 29.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,665 shares of the specialty pharmaceutical company’s stock after selling 4,800 shares during the period. First Allied Advisory Services Inc.’s holdings in Valeant Pharmaceuticals International were worth $168,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. AMP Capital Investors Ltd boosted its position in Valeant Pharmaceuticals International by 6.3% during the 3rd quarter. AMP Capital Investors Ltd now owns 142,910 shares of the specialty pharmaceutical company’s stock worth $2,043,000 after purchasing an additional 8,484 shares during the period. Stifel Financial Corp boosted its position in Valeant Pharmaceuticals International by 18.4% during the 3rd quarter. Stifel Financial Corp now owns 236,576 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after purchasing an additional 36,705 shares during the period. Commerzbank Aktiengesellschaft FI boosted its position in Valeant Pharmaceuticals International by 88.5% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 830,988 shares of the specialty pharmaceutical company’s stock worth $11,908,000 after purchasing an additional 390,115 shares during the period. Dimensional Fund Advisors LP boosted its position in Valeant Pharmaceuticals International by 327.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock worth $64,086,000 after purchasing an additional 3,426,410 shares during the period. Finally, Partners Value Investments LP boosted its position in Valeant Pharmaceuticals International by 31.7% during the 3rd quarter. Partners Value Investments LP now owns 694,100 shares of the specialty pharmaceutical company’s stock worth $9,946,000 after purchasing an additional 167,000 shares during the period. 49.49% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded up $0.03 during trading hours on Friday, reaching $19.71. 23,751,547 shares of the company’s stock were exchanged, compared to its average volume of 21,811,284. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84. The stock has a market cap of $6,870.75, a PE ratio of 3.20, a P/E/G ratio of 0.54 and a beta of -0.22. Valeant Pharmaceuticals International, Inc. has a one year low of $8.31 and a one year high of $22.81.

In other news, Director John Paulson acquired 344,216 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was bought at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the transaction, the director now directly owns 94,559 shares in the company, valued at approximately $1,361,649.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.87% of the company’s stock.

A number of analysts recently weighed in on VRX shares. BMO Capital Markets upped their price target on shares of Valeant Pharmaceuticals International from $16.00 to $17.00 and gave the stock a “market perform” rating in a research report on Monday, November 13th. Vetr raised shares of Valeant Pharmaceuticals International from a “buy” rating to a “strong-buy” rating and set a $14.26 price target for the company in a research report on Thursday, October 19th. ValuEngine cut shares of Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank of Canada decreased their price target on shares of Valeant Pharmaceuticals International from $21.00 to $18.00 and set a “sector perform” rating for the company in a research report on Friday, October 20th. Finally, Deutsche Bank set a $18.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Thursday, November 16th. Six investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average target price of $17.56.

TRADEMARK VIOLATION WARNING: This report was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/12/17/first-allied-advisory-services-inc-decreases-position-in-valeant-pharmaceuticals-international-inc-vrx.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply